Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration resistant prostate cancer and resistance to AR targeting therapies including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Jun 21 [Epub ahead of print]
Adam Sharp, Jonathan Welti, Julian Blagg, Johann S de Bono
Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust., Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research., Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research., Prostate Cancer Targeted Therapy Group, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust .